JP2005505499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505499A5 JP2005505499A5 JP2002584819A JP2002584819A JP2005505499A5 JP 2005505499 A5 JP2005505499 A5 JP 2005505499A5 JP 2002584819 A JP2002584819 A JP 2002584819A JP 2002584819 A JP2002584819 A JP 2002584819A JP 2005505499 A5 JP2005505499 A5 JP 2005505499A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alkyl
- compound
- pharmaceutically acceptable
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 48
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- 150000001875 compounds Chemical class 0.000 claims 33
- 239000003814 drug Substances 0.000 claims 26
- 125000003342 alkenyl group Chemical group 0.000 claims 24
- 125000000304 alkynyl group Chemical group 0.000 claims 24
- 229940124597 therapeutic agent Drugs 0.000 claims 24
- 125000003545 alkoxy group Chemical group 0.000 claims 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 20
- 229940002612 prodrug Drugs 0.000 claims 19
- 239000000651 prodrug Substances 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- 150000008064 anhydrides Chemical class 0.000 claims 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 8
- -1 phenalkyl Chemical group 0.000 claims 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 208000036142 Viral infection Diseases 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 230000009385 viral infection Effects 0.000 claims 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 239000003443 antiviral agent Substances 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 241001529453 unidentified herpesvirus Species 0.000 claims 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 210000004962 mammalian cell Anatomy 0.000 claims 3
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 claims 2
- 229960002756 azacitidine Drugs 0.000 claims 2
- 229960002436 cladribine Drugs 0.000 claims 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960001428 mercaptopurine Drugs 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- 230000029812 viral genome replication Effects 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000531123 GB virus C Species 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000005331 Hepatitis D Diseases 0.000 claims 1
- 241000724675 Hepatitis E virus Species 0.000 claims 1
- 241000724709 Hepatitis delta virus Species 0.000 claims 1
- 241000709721 Hepatovirus A Species 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000701027 Human herpesvirus 6 Species 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 1
- 208000018501 Lymphatic disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 210000001130 astrocyte Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 201000010284 hepatitis E Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000018555 lymphatic system disease Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000004498 neuroglial cell Anatomy 0.000 claims 1
- 208000017443 reproductive system disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/844,201 US7026469B2 (en) | 2000-10-19 | 2001-04-27 | Compositions and methods of double-targeting virus infections and cancer cells |
| US09/844,201 | 2001-04-27 | ||
| PCT/US2002/013338 WO2002087465A2 (en) | 2001-04-27 | 2002-04-26 | Compositions and methods of double-targeting virus infections and cancer cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005505499A JP2005505499A (ja) | 2005-02-24 |
| JP2005505499A5 true JP2005505499A5 (enExample) | 2006-01-05 |
| JP4782365B2 JP4782365B2 (ja) | 2011-09-28 |
Family
ID=25292094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002584819A Expired - Fee Related JP4782365B2 (ja) | 2001-04-27 | 2002-04-26 | ウイルス感染症と癌細胞を二重ターゲッティングする組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7026469B2 (enExample) |
| EP (1) | EP1389970A4 (enExample) |
| JP (1) | JP4782365B2 (enExample) |
| AU (1) | AU2002252731A1 (enExample) |
| CA (1) | CA2445565C (enExample) |
| WO (1) | WO2002087465A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1460082A1 (en) * | 2003-03-19 | 2004-09-22 | Heidelberg Pharma Holding GmbH | Phospholipid esters of clofarabine derivatives |
| US20050187192A1 (en) * | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
| US20050187191A1 (en) * | 2004-02-20 | 2005-08-25 | Kucera Louis S. | Methods and compositions for the treatment of respiratory syncytial virus |
| LT2574341T (lt) | 2004-03-29 | 2017-09-11 | University Of South Florida | Navikų ir vėžio efektyvus gydymas triciribino fosfatu |
| US8101745B2 (en) | 2004-12-16 | 2012-01-24 | The Regents Of The University Of California | Lung-targeted drugs |
| WO2006110655A2 (en) | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| EP1865967A4 (en) * | 2005-04-08 | 2011-02-09 | Chimerix Inc | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES |
| EP2012799B1 (en) * | 2006-05-03 | 2016-08-24 | Chimerix, Inc. | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates |
| US20080249066A1 (en) * | 2007-03-23 | 2008-10-09 | Ardea Biosciences, Inc. | Antiviral compounds and compositions |
| WO2009049089A1 (en) | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging |
| US9446150B2 (en) | 2007-10-09 | 2016-09-20 | Washington University | Particles for imaging |
| EP3085377A1 (en) * | 2008-01-25 | 2016-10-26 | Chimerix, Inc. | Methods of treating viral infections |
| US8999960B2 (en) | 2008-10-08 | 2015-04-07 | Vascular Biogenics Ltd. | Oxidized thiophospholipid compounds and uses thereof |
| EP2826369A3 (en) * | 2008-11-06 | 2015-03-18 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
| WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| WO2011084700A1 (en) | 2009-12-17 | 2011-07-14 | The Washington University | Antithrombotic nanoparticle |
| US9808500B2 (en) | 2009-12-17 | 2017-11-07 | Washington University | Antithrombotic nanoparticle |
| HUE032860T2 (en) | 2010-02-12 | 2017-11-28 | Chimerix Inc | A method for treating a virus infection |
| AU2011239414A1 (en) | 2010-04-15 | 2012-11-08 | The Washington University | Prodrug compositions, prodrug nanoparticles, and methods of use thereof |
| US9278135B2 (en) | 2010-04-26 | 2016-03-08 | Chimerix Inc. | Methods of treating retroviral infections and related dosage regimes |
| US9192680B2 (en) | 2010-06-01 | 2015-11-24 | Aposense Ltd. | Pharmaceutical compounds |
| US8530444B2 (en) * | 2010-06-01 | 2013-09-10 | Aposense Ltd. | Pharmaceutical compounds |
| SI2970346T1 (sl) | 2013-03-15 | 2018-12-31 | The Regents Of The University Of California | Aciklični diestri nukleozid fosfonata |
| PT3194411T (pt) | 2014-09-15 | 2022-06-06 | Univ California | Análogos de nucleótidos |
| CA2968790A1 (en) | 2014-11-26 | 2016-06-02 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| EP3875462A1 (en) | 2015-09-15 | 2021-09-08 | The Regents of The University of California | Nucleotide analogs |
| WO2024020127A1 (en) | 2022-07-21 | 2024-01-25 | Antiva Biosciences, Inc. | Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2108765A (en) * | 1938-02-15 | Preserving and disinfecting media | ||
| DE279249C (enExample) | ||||
| US2087132A (en) * | 1933-04-13 | 1937-07-13 | Alba Pharmaceutical Company In | Quaternary ammonium compounds |
| US2086585A (en) * | 1933-04-13 | 1937-07-13 | Alba Pharmaceutical Company In | Quaternary ammonium compounds |
| US2209383A (en) * | 1938-03-05 | 1940-07-30 | Rohm & Haas | Process of waterproofing fabrics |
| US2445393A (en) * | 1944-03-08 | 1948-07-20 | Rhone Poulenc Sa | New amino-derivatives of dioxa-cyclopentane |
| US2439969A (en) * | 1944-04-17 | 1948-04-20 | Rhone Poulenc Sa | Amino-dioxacyclopentanes |
| US2513747A (en) * | 1945-10-04 | 1950-07-04 | Ciba Ltd | Cyclic amino-acetals |
| US2606909A (en) * | 1947-08-01 | 1952-08-12 | Univ Michigan | Basic dioxolanes |
| US2689790A (en) * | 1951-09-26 | 1954-09-21 | Monsanto Chemicals | Nitrogenous compound herbicides |
| NL189533C (nl) * | 1953-07-29 | Ates Componenti Elettron | Werkwijze voor het aanbrengen van een kunststofhouder met warmte-afvoer rond een geintegreerde schakeling, alsmede combinatie van een matrijs en een warmte-afvoerelement voor gebruik bij deze werkwijze. | |
| US3054678A (en) * | 1958-04-16 | 1962-09-18 | Michener Harold David | Preservation process with quaternary ammonium compounds |
| DE1619043B2 (de) | 1967-04-07 | 1977-11-03 | Hoechst Ag, 6000 Frankfurt | Mittel zum weichmachen von textilien und gleichzeitigem vermitteln einer guten saugfaehigkeit |
| US4119714A (en) * | 1970-02-27 | 1978-10-10 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. | Glycerin-alkylether-(1)-phosphoric acid-(3)-monocholine esters as enhancers of the natural resistance of the mammalian organism against non-carcinogenic pathogens |
| DE2033359C3 (de) * | 1970-07-06 | 1980-02-14 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen | Acylpropandiol-(l,3)-phosphorsäuremono-cholinester und Verfahren zu deren Herstellung |
| JPS49100224U (enExample) | 1972-12-19 | 1974-08-29 | ||
| JPS49100224A (enExample) | 1973-01-29 | 1974-09-21 | ||
| US4093714A (en) * | 1974-03-15 | 1978-06-06 | Icn Pharmaceuticals, Inc. | 9β-D-Arabinofuranosylpurine nucleotides and method of use |
| US4159988A (en) * | 1974-08-06 | 1979-07-03 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Synthetic phospholipids, a process for their manufacture and their use |
| FR2356425A1 (fr) * | 1976-07-01 | 1978-01-27 | Roussel Uclaf | Application a titre de medicaments de derives organiques de la montmorillonite |
| US4291024A (en) * | 1978-04-10 | 1981-09-22 | Turcotte Joseph G | Cytotoxic liponucleotide analogs |
| DE2820893C2 (de) * | 1978-05-12 | 1986-02-20 | A. Nattermann & Cie GmbH, 5000 Köln | Strukturanaloga von natürlichen Phospholipiden und Verfahren zur Herstellung dieser Verbindungen |
| US4235877A (en) * | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4329302A (en) * | 1980-06-27 | 1982-05-11 | Board Of Regents, The University Of Texas System | Synthetic phosphoglycerides possessing platelet activating properties |
| US4444766A (en) * | 1980-10-21 | 1984-04-24 | Boehringer Mannheim Gmbh | Sulfur-containing phospholipid compounds and therapeutic compositions |
| JPS5772914A (en) * | 1980-10-22 | 1982-05-07 | Takeda Chem Ind Ltd | Antitumor agent |
| US4471113A (en) * | 1982-02-03 | 1984-09-11 | The United States Of America As Represented By The Department Of Energy | Prodrugs based on phospholipid-nucleoside conjugates |
| EP0094586A3 (en) | 1982-05-13 | 1984-06-06 | Ono Pharmaceutical Co., Ltd. | Glycerol derivatives, process for preparing same and pharmaceutical composition containing same |
| US4661509A (en) * | 1982-09-28 | 1987-04-28 | Gordon Arnold Z | Methods for treating leukopenia |
| JPS5988447A (ja) | 1982-11-11 | 1984-05-22 | Ono Pharmaceut Co Ltd | グリセリン誘導体、その製造方法及びその誘導体を含有する薬剤 |
| FR2540122B1 (fr) * | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| JPS60100544A (ja) | 1983-11-08 | 1985-06-04 | Ono Pharmaceut Co Ltd | 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤 |
| JPS60104066A (ja) | 1983-11-10 | 1985-06-08 | Ono Pharmaceut Co Ltd | グリセリン誘導体 |
| JPS60105650A (ja) | 1983-11-14 | 1985-06-11 | Ono Pharmaceut Co Ltd | グリセリン誘導体、その製造方法及びその誘導体を含有する薬剤 |
| US4540521A (en) * | 1984-01-16 | 1985-09-10 | National Distillers And Chemical Corporation | Liquid quaternary ammonium antistatic compositions |
| US4622392A (en) * | 1984-06-21 | 1986-11-11 | Health Research Inc. (Roswell Park Division) | Thiophospholipid conjugates of antitumor agents |
| US4826823A (en) * | 1985-02-05 | 1989-05-02 | Warner-Lambert Company | Methods of using 2-chloro-2'-deoxyadenosine-5'-phosphate and its salts |
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| US4797479A (en) * | 1985-04-15 | 1989-01-10 | Toyo Jozo Kabushiki Kaisha | Nucleoside-phospholipid conjugate |
| JPS61238793A (ja) | 1985-04-17 | 1986-10-24 | Toyo Jozo Co Ltd | 新規リン脂質誘導体 |
| US4619917A (en) * | 1985-07-18 | 1986-10-28 | Sandoz Pharm. Corp. | Substituted 2-furanyl- or 5-oxo-2-furanyl methoxy phosphoryl alkyl cyclimmonium salts |
| CA1280369C (en) * | 1985-12-04 | 1991-02-19 | Hansjorg Eibl | Pharmaceutical with anti-tumor effect |
| US4841039A (en) * | 1986-05-01 | 1989-06-20 | Emory University | 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents |
| DE3619748A1 (de) | 1986-06-12 | 1987-12-17 | Merz & Co Gmbh & Co | Antimikrobielle mittel |
| US4816450A (en) * | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
| EP0262876B1 (en) * | 1986-09-27 | 1992-04-29 | Toyo Jozo Kabushiki Kaisha | Nucleoside-phospholipid conjugate |
| US4880782A (en) * | 1986-11-21 | 1989-11-14 | Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. | Method of treating viral infections in humans and compositions therefor |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| JP2598643B2 (ja) | 1987-07-24 | 1997-04-09 | わかもと製薬株式会社 | 抗アレルギー剤 |
| DE3726945A1 (de) | 1987-08-13 | 1989-02-23 | Dietl Hans | L-carnitinderivate der valproinsaeure und diese enthaltende arzneimittel |
| US4894389A (en) | 1987-10-02 | 1990-01-16 | Merrell Dow Pharmaceuticals Inc. | Novel aminoalkyl-substituted heterocyclic sulfur compounds |
| US4997761A (en) * | 1987-10-06 | 1991-03-05 | Houston Biotechnology Incorporated | Phosphatidyl treatment of viral disease |
| US4797497A (en) | 1988-02-25 | 1989-01-10 | Amoco Corporation | Trimellitic anhydride purification process |
| EP0335396A1 (en) | 1988-04-01 | 1989-10-04 | MAGIS FARMACEUTICI S.p.A. | Glycero-phosphoric and -diphosphoric acids derivatives of L-carnitine or L-carnitine esters |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| EP0348859A1 (en) | 1988-07-01 | 1990-01-03 | MAGIS FARMACEUTICI S.p.A. | 1,2-di-O-acyl glycero(DI)phosphate of L-carnitine and its derivatives, a process for their preparation and pharmaceutical formulations which contain them |
| US5817638A (en) * | 1988-07-07 | 1998-10-06 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| CA2001401A1 (en) * | 1988-10-25 | 1990-04-25 | Claude Piantadosi | Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions |
| GB8827337D0 (en) | 1988-11-23 | 1988-12-29 | Medical Res Council | Nucleoside analogues |
| DD279249A1 (de) | 1989-01-01 | 1990-05-30 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diphosphat-1,2-di-o-alkylglycerolen und deren salzen |
| US5221696A (en) * | 1989-03-29 | 1993-06-22 | Alcon Laboratories, Inc. | Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs |
| FI902821A7 (fi) | 1989-06-12 | 1990-12-13 | Res Foundation For Mental Hygiene | Infektion leviämisen vähentäminen verenkäsittelylaitteistolla |
| US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| DE3929217A1 (de) | 1989-09-02 | 1991-03-07 | Boehringer Mannheim Gmbh | Verwendung von phospholipid-derivaten als antivirale arzneimittel und neue phospholipide |
| DE3934820A1 (de) | 1989-10-19 | 1991-04-25 | Boehringer Mannheim Gmbh | Verwendung von lecithin-analoga als antivirale arzneimittel und neue derivate |
| MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| GB2239243B (en) | 1989-12-22 | 1993-05-12 | Scras | Glycerol derivatives |
| DE3942933A1 (de) | 1989-12-23 | 1991-06-27 | Boehringer Mannheim Gmbh | Verwendung von alkylphospholipiden als antivirale arzneimittel und neue phospholipid-derivate |
| US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
| DE4010228A1 (de) | 1990-03-30 | 1991-10-02 | Werner E G Prof Dr Mueller | Verfahren zur herstellung eines mittels gegen virale infektionen, vorzugsweise gegen aids |
| US5134394A (en) * | 1990-04-12 | 1992-07-28 | Beadle Leigh P | Light aircraft navigation apparatus |
| JPH05507279A (ja) | 1990-05-29 | 1993-10-21 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | グリセロールジ―およびトリホスフェート誘導体の合成 |
| ATE137242T1 (de) | 1990-06-15 | 1996-05-15 | Univ Wake Forest | Kovalente-ther lipidnukleosid-konjugate |
| US5138045A (en) * | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| DE4026265A1 (de) | 1990-08-20 | 1992-02-27 | Boehringer Mannheim Gmbh | Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel |
| US5563257A (en) * | 1990-08-20 | 1996-10-08 | Boehringer Mannheim Gmbh | Phospholipid derivatives of nucleosides |
| TW207544B (enExample) * | 1990-08-20 | 1993-06-11 | Boehringer Mannheim Gmbh | |
| JPH06504429A (ja) | 1990-10-09 | 1994-05-26 | ネクスター・フアーマシユーテイカルズ・インコーポレイテツド | ウイルス複製の阻害 |
| DE4111730A1 (de) | 1991-04-10 | 1992-10-15 | Knoll Ag | Neue cytarabin-derivate, ihre herstellung und verwendung |
| WO1993000910A1 (en) | 1991-07-12 | 1993-01-21 | Vical, Inc. | Antiviral liponucleosides: treatment of hepatitis b |
| ES2153365T3 (es) | 1991-10-28 | 2001-03-01 | Dennis L Fost | Composiciones fosfolipidas antimicrobianas. |
| DE4204032A1 (de) | 1992-02-12 | 1993-08-19 | Boehringer Mannheim Gmbh | Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel |
| DE4204031A1 (de) | 1992-02-12 | 1993-08-19 | Boehringer Mannheim Gmbh | Neue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel |
| GB9204015D0 (en) | 1992-02-25 | 1992-04-08 | Wellcome Found | Therapeutic nucleosides |
| US6602861B1 (en) | 1992-04-16 | 2003-08-05 | Research Corporation Technologies, Inc. | Acylated phospholipid drugs |
| US5512671A (en) | 1993-02-16 | 1996-04-30 | Wake Forest University | Ether lipid-nucleoside covalent conjugates |
| DE69419244T2 (de) * | 1993-02-24 | 1999-10-14 | Wang | Zusammensetzungen und methoden zur anwendung von reaktiven antiviralen polymeren |
| IL105244A (en) | 1993-03-31 | 2003-07-31 | Dpharm Ltd | Prodrugs with enhanced penetration into cells |
| US6413949B1 (en) | 1995-06-07 | 2002-07-02 | D-Pharm, Ltd. | Prodrugs with enhanced penetration into cells |
| EP0702556B1 (en) * | 1993-06-10 | 2002-10-23 | Wake Forest University | (phospho)lipids for combatting hepatitis b virus infection |
| ATE199906T1 (de) | 1993-06-29 | 2001-04-15 | Mitsubishi Chem Corp | Phosphonat-nukleotid ester-derivate |
| DE4321978A1 (de) | 1993-07-01 | 1995-01-12 | Boehringer Mannheim Gmbh | Liponucleotide von Desoxynucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel |
| WO1995003056A1 (en) * | 1993-07-19 | 1995-02-02 | Tokyo Tanabe Company Limited | Hepatitis c virus proliferation inhibitor |
| DE4402492A1 (de) | 1994-01-28 | 1995-08-03 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von unsymmetrischen Phosphorsäurediestern |
| DE4418690A1 (de) | 1994-05-28 | 1996-01-11 | Boehringer Mannheim Gmbh | Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel |
| ATE395922T1 (de) * | 1994-08-29 | 2008-06-15 | Univ Wake Forest | Lipid-analoge zur behandlung von viralen infektionen |
| EP0791056B1 (de) | 1994-11-12 | 2005-03-30 | Heidelberg Pharma GmbH | Lipidspaltender enzymkomplex |
| JP3786447B2 (ja) | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Ｃ型肝炎の予防・治療剤 |
| US5830905A (en) * | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| US5633388A (en) * | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| US5891874A (en) * | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
| JP3927630B2 (ja) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウイルス感染症の予防・治療剤 |
| US5922757A (en) * | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
| IN183120B (enExample) | 1996-10-18 | 1999-09-11 | Vertex Pharma | |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| PT1012180E (pt) | 1997-08-11 | 2005-04-29 | Boehringer Ingelheim Ca Ltd | Analogos de peptidos inibidores da hepatite c |
| GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
| US6243759B1 (en) * | 1998-05-08 | 2001-06-05 | International Business Machines Corporation | Method and system for configuring dynamic interfaces |
| IL131887A0 (en) * | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
| US6670341B1 (en) * | 1999-10-28 | 2003-12-30 | Wake Forest University Health Sciences | Compositions and methods for double-targeting virus infections and targeting cancer cells |
| JP4213841B2 (ja) | 2000-03-23 | 2009-01-21 | 大成建設株式会社 | 仮支承の施工方法 |
-
2001
- 2001-04-27 US US09/844,201 patent/US7026469B2/en not_active Expired - Lifetime
-
2002
- 2002-04-26 AU AU2002252731A patent/AU2002252731A1/en not_active Abandoned
- 2002-04-26 CA CA2445565A patent/CA2445565C/en not_active Expired - Fee Related
- 2002-04-26 JP JP2002584819A patent/JP4782365B2/ja not_active Expired - Fee Related
- 2002-04-26 WO PCT/US2002/013338 patent/WO2002087465A2/en not_active Ceased
- 2002-04-26 EP EP02721822A patent/EP1389970A4/en not_active Withdrawn
-
2006
- 2006-04-06 US US11/398,529 patent/US7638528B2/en not_active Expired - Fee Related
-
2009
- 2009-12-02 US US12/629,387 patent/US8138200B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005505499A5 (enExample) | ||
| AU2006294807B2 (en) | Modified 4'-nucleosides as antiviral agents | |
| JP2851094B2 (ja) | ピリミジン誘導体 | |
| EP2615101B1 (en) | Nucleoside derivatives, synthesis methods and uses thereof for preparing anti-tumor and anti-virus medicaments | |
| ES2242965T3 (es) | Derivados de aril-ester fosforamidato de 2', 3'-didehidronucleosidos. | |
| ES2240645T3 (es) | Nuevos derivados de pirazina o sus sales, composiciones farmaceuticas que contienen estos derivados o sus sales e intermedios utilizados en su preparacion. | |
| US20060074035A1 (en) | Dinucleotide inhibitors of de novo RNA polymerases for treatment or prevention of viral infections | |
| JP2010515760A5 (enExample) | ||
| EP0322384A1 (en) | Nucleosides for use in therapy | |
| EP1858889A1 (en) | Bicyclic nucleosides and nucleotides as therapeutic agents | |
| JP2004505889A (ja) | ヌクレオシド化合物およびその使用 | |
| ZA200400925B (en) | Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | |
| RU2006109491A (ru) | Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств | |
| CA2389544A1 (en) | Compositions and methods for double-targeting virus infections and targeting cancer cells | |
| JP2010526834A5 (enExample) | ||
| RU2009132512A (ru) | Аналоги 2-5а и способы их применения | |
| SI2097434T1 (sl) | Nukleozidni aril fosforamidati in njihova uporaba kot protivirusna sredstva za zdravljenje virusa hepatitisa C | |
| JP2009504704A (ja) | 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート | |
| MX2009012433A (es) | Azido nucleosidos de purina para el tratamiento de infecciones virales. | |
| EP0642525B1 (en) | Nucleosides being O-acylated with a mono-unsaturated omega-9 C18 or C20 fatty acid | |
| JP2003520783A5 (enExample) | ||
| US20180030080A1 (en) | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use | |
| CA2287370A1 (en) | Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides | |
| Meng et al. | 2′-Fluorinated nucleoside chemistry for new drug discovery: achievements and prospects | |
| WO2018067241A1 (en) | Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof |